Search results for "Uterine sarcoma"

showing 5 items of 5 documents

Essential Oils, Pituranthos chloranthus and Teucrium ramosissimum, Chemosensitize Resistant Human Uterine Sarcoma MES-SA/Dx5 Cells to Doxorubicin by …

2021

The multidrug resistance phenotype is a global phenomenon and causes chemotherapy failure in various cancers, such as in uterine sarcomas that have a high mortality rate. To overcome this phenotype, there is growing research interest in developing new treatment strategies. In this study, we highlight the potential of two essential oils from the Apiaceae family, Pituranthos chloranthus (PC) and Teucrium ramosissimum Desf. (TR), to act as chemopreventive and chemosensitizing agents against two uterine sarcoma cell lines, MES-SA and P-gp-overexpressing MES-SA/Dx5 cells. We found that PC and TR were able to inhibit the cell viability of sensitive MES-SA and resistant MES-SA/Dx5 cells by a sligh…

0301 basic medicineProgrammed cell deathuterine sarcomaP-glycoproteindoxorubicin03 medical and health sciences0302 clinical medicinemedicineDoxorubicinTX341-641Viability assayessential oilsP-glycoproteinNutrition and DieteticsbiologyChemistryNutrition. Foods and food supplyCell cyclechemosensitization030104 developmental biologyApoptosisCell culture030220 oncology & carcinogenesisCancer researchbiology.proteinIntracellularFood Sciencemedicine.drugNutrients
researchProduct

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgeme…

2007

Abstract Objective. A multicenter non-randomized phase II study was initiated to evaluate tolerability and efficacy of pegylated liposomal doxorubicin (PLD) in combination with carboplatin in gynecologic malignancies. Methods. One hundred forty women with recurrent or advanced endometrial ( n =31), cervical or vaginal cancer ( n =31), uterine sarcomas ( n =11), or recurrent platinum-sensitive ovarian cancer ( n =67) received six courses of PLD 40 mg/m 2 and carboplatin (AUC 6) every 28 days. Results. Hematological toxicities with NCI-CTC grade 3/4 were anemia in 8%, thrombocytopenia in 14%, neutropenia in 24%, and febrile neutropenia in 2% of 652 cycles. Grade 3/4 non-hematological toxiciti…

AdultOncologymedicine.medical_specialtyGenital Neoplasms FemalePhases of clinical researchNeutropeniaGastroenterologyDrug Administration ScheduleCarboplatinPolyethylene Glycolschemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesInfusions IntravenousAgedAged 80 and overVaginal cancerUterine sarcomabusiness.industryEndometrial cancerObstetrics and GynecologyMiddle Agedmedicine.diseaseCarboplatinOncologychemistryDoxorubicinFemaleOvarian cancerbusinessFebrile neutropeniaGynecologic Oncology
researchProduct

Cerebral metastases of an endometrial stromal sarcoma: report of the first case.

2012

Endometrial stromal sarcomas (ESSs) of the uterus are rare gynecological malignancies. Common locations of distant metastases are vagina, vulva, lung, mediastinum, abdomen, bones and ovaries.We present the case of a 69-year-old woman with a Federation of Gynecology and Obstetrics (FIGO) IIb (classification 2009) ESS of the uterus of high-grade malignancy. Initially, a hysterectomy Piver II and total colpectomy were performed, followed by pelvic field irradiation. 8 months later, the patient suffered seizures and hemiparesis. A computed tomography (CT) scan revealed cerebral metastases, and irradiation of the brain was initiated. After completion of the staging examinations, additional metas…

Cancer Researchmedicine.medical_specialtyPathologyStromal cellSarcoma Endometrial StromalUterusVulvamedicineHumansAgedEndometrial stromal sarcomaLungUterine sarcomaurogenital systembusiness.industryBrain NeoplasmsHematologyGeneral Medicinemedicine.diseaseEndometrial Neoplasmsmedicine.anatomical_structureTreatment OutcomeOncologyVaginaFemaleRadiologybusinessOnkologie
researchProduct

Uterine sarcomas: A critical review of the literature

2023

This review aims to provide a comprehensive description of surgical approaches for the management of uterine sarcomas. Uterine sarcomas are rare uterine neoplasms. Frequently, diagnosis is made after hysterectomy or myomectomy scheduled for presumed benign leiomyomas. The gold standard for surgical treatment of uterine sarcomas is hysterectomy with bilateral salpingo-oophorectomy. It is possible to adopt a fertility-sparing approach for those patients who wish to maintain their fertility. The role of pelvic lymphadenectomy is controversial; in fact, removal of lymph nodes is only recommended in the case of radiological suspicion of nodal involvement. Use of a morcellator is associated with …

Fertility-sparing surgeryMesenchymal tumourUterine sarcoma.Gynaecologic surgeryGynaecologic oncologySettore MED/40 - Ginecologia E Ostetricia
researchProduct

Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis

2020

Background: Although the use of adjuvant chemotherapy (AC) appears to be increasing over the past few years, several clinical trials and previous meta-analyses failed to determine whether AC could improve clinical outcomes in uterine leiomyosarcoma (uLMS). The aim of this systematic review and meta-analysis was to compare AC (with or without radiotherapy) versus observation (obs) after primary surgery in early stage uLMS. Materials and Methods: Randomized controlled (RCTs) and non-randomized studies (NRSs) were retrieved. Outcomes of interest were as follows: distant recurrence rate, locoregional recurrence rate and overall recurrence rate. Results about distant recurrence rate, locoregiona…

OncologyCancer Researchmedicine.medical_specialtyuterine sarcomamedicine.medical_treatmentchemotherapylcsh:RC254-282meta-analysiArticleNOuterine leiomyosarcoma03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapy030212 general & internal medicineStage (cooking)meta-analysis uterine leiomyosarcoma uterine sarcoma adjuvant therapy chemotherapyUterine sarcomabusiness.industryadjuvant therapyOdds ratiomedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalClinical trialRadiation therapymeta-analysisadjuvant therapy chemotherapyOncology030220 oncology & carcinogenesisMeta-analysisAdjuvant therapy Uterine sarcoma Uterine leiomyosarcoma Meta-analysis ChemotherapybusinessCancers
researchProduct